PRODUCT TYPES – Page 22

Biologic glycosylation shift (CQAs) outside trend during deviation investigation board review: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms that indicate a deviation in glycosylation patterns is the first step in the investigation process. Key signals may include:Click to read the full article.

Carryover contamination risk in hormonal manufacturing: GMP investigation and containment strategy

Signals of potential carryover contamination can manifest in various ways during manufacturing and quality control processes. Some common symptoms may include:Click to read the full article.

Biologic charge variant shift (CEX) OOS after filling line intervention: patient safety impact assessment and batch disposition governance

The first step in addressing a biologic charge variant shift is to identify the symptoms or signals that alert personnel to potential issues. Common indicators of a CEX OOS incident…

Cleaning validation failure during multi-product campaign: GMP investigation and containment strategy

The initial step in handling a cleaning validation failure is recognizing the symptoms or signals that indicate a potential problem. Common signs may include:Click to read the full article.

Biologic viral clearance validation gap during stability pull at 3/6/12 months: CAPA package with CQA/CPP risk assessment and effectiveness verification

The first step in any investigation is recognizing the early warning signs that indicate a potential issue. For biologics, the following signals may suggest a viral clearance validation gap:Click to…

Blend uniformity OOS in hormonal manufacturing: CAPA aligned to regulatory expectations

Identifying symptoms or signals of a blend uniformity OOS event is the first step in addressing the issue. Common signals may include:Click to read the full article.

Biologic charge variant shift (CEX) OOS after equipment qualification update: viral safety and contamination response plan with inspection-ready evidence

When handling biologics, identifying symptoms on the manufacturing floor or in the laboratory environment is crucial for initiating an appropriate response. For a biologic charge variant shift resulting in an…

Stability degradation during inspection readiness: CAPA aligned to regulatory expectations

Identifying symptoms or signals indicative of stability degradation is critical to mitigating potential regulatory compliance issues during inspections. Common signals may include:Click to read the full article.

Biologic cold chain excursion impact after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Identifying symptoms indicating a cold chain excursion is the first step in an effective investigation. Signals may arise from both the packaging of biologics and monitoring systems. Key symptoms include:Click…

Potency variability during multi-product campaign: GMP investigation and containment strategy

Identifying the symptoms of potency variability during a multi-product campaign is crucial. Common signals include:Click to read the full article.

Biologic cell culture contamination event during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

The first step in identifying a biologic cell culture contamination event is recognizing the symptoms or signals that indicate a potential problem. These include:Click to read the full article.

Carryover contamination risk after cleaning cycle change: GMP investigation and containment strategy

Symptoms of carryover contamination may manifest in various forms, impacting product quality and regulatory compliance. These symptoms can be divided into two categories: visible signs (such as particulate matter in…